Business Wire

NJ-OPENGEAR

22.2.2024 07:01:34 CET | Business Wire | Press release

Share
Opengear Launches Enhanced Technical Certification Program

Opengear, a Digi International company (NASDAQ, DGII, www.digi.com) and provider of secure and Smart Out of Band management solutions, today announced the launch of its enhanced Technical Certification Program, aimed at empowering IT professionals and network engineers in the Opengear network of channel and distribution organizations with comprehensive technical expertise to address evolving network challenges on the First Day, Worst Day, and Every Day.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240221739136/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Opengear launches its enhanced Technical Certification Program, providing technical professionals with the knowledge and expertise required to effectively navigate and manage complex network infrastructures. (Graphic: Business Wire)

Developed by Opengear's channel engineers, the Technical Certification Program is a robust e-learning initiative designed specifically to equip solution architects and sales engineers with the skills needed to manage the toughest network challenges. With the industry witnessing a constant influx of new technologies, advanced networking architectures, and increased demand for network resilience, professionals need to stay ahead of the curve — continually enhancing their skills to effectively navigate and manage complex network infrastructures, as well as address the challenges posed by emerging technologies, cybersecurity threats, and the need for robust network automation.

“Opengear's channel plays a pivotal role in our market success,” said Tracy Collins, Opengear’s Vice President of Sales, Americas. “We're therefore thrilled to introduce our comprehensive Technical Certification Program, which is tailored to meet specific needs and empower our valued channel organizations. Equipping them with in-depth knowledge of Opengear’s solutions aligns with our continued commitment to helping them deliver enhanced value to their end customers — a cornerstone of our business philosophy.”

Directly tackling key industry issues, the new program provides end-to-end education and training, enabling participants to gain deeper product knowledge and understanding of Opengear's solutions, including OGCS, NGCS, and LH modules. Customers will benefit from enhanced support, faster product integration, and access to a skilled reseller’s professional network. The program certification empowers channel organizations with a competitive advantage — fostering successful and efficient deployments of Opengear solutions.

Features and benefits of the Opengear Technical Certification Program include:

  • Empowerment and Expertise: Equips professionals with the technical education and expertise needed to address the evolving demands of network management using Opengear solutions.

  • Practical Application: Program focuses on real-world scenarios and problem solving to ensure practical application of knowledge.

  • Global Accessibility: Available to Opengear distributors and channel organizations worldwide, facilitating learning and certification regardless of geographical location.

  • Cost-Free Learning: Accessible through Opengear’s Partner Portal at no additional cost.

  • First Day, Worst Day, Every Day: Addresses critical network challenges and prepares resellers on every front, from routine operations to crisis management with Opengear's robust solutions.

“Designed exclusively for the technical talents within our channel community, Opengear’s Technical Certification Program is more than just training; it's a commitment to elevating technical excellence,” said Dan Baxter, Director, Sales Engineering, Americas at Opengear. “We believe in investing in the technical acumen of our distributors and resellers because in today's intricate networking landscape, a certified team translates to empowered organizations. This program provides our channel technical community with technical resources and the certification they deserve, fostering expertise that benefits both their personal growth and the success of the entire team.”

Members or our channel organizations can register for the Opengear Technical Certification Program by logging into the Partner Portal at https://partners.opengear.com and accessing the training section.

For more information about Opengear, visit https://www.opengear.com/.

About Opengear

Opengear, a Digi International company, delivers secure, resilient access and automation to support critical IT infrastructure on the First Day, Worst Day, and Every Day. Through presence and proximity, Opengear solutions enable provisioning, orchestration, and remote management of network devices through innovative software and appliances. Opengear solutions are trusted by global organizations across financial, digital communications, retail, and manufacturing sectors. The company is headquartered in New Jersey, with an R&D center in Brisbane, Australia. For more information, visit www.opengear.com/.

About Digi International

Digi International (NASDAQ: DGII) is a leading global provider of business and mission-critical Internet of Things (IoT) connectivity products and solutions. We help our customers create next-generation connected products and solutions to deploy, monitor, and manage critical communications infrastructures and compliance standards in demanding environments with high levels of security, relentless reliability, and bulletproof performance. Founded in 1985, the company has helped customers connect more than 100 million things — and counting. For more information, visit www.digi.com, or call 877-912-3444 (U.S.) or 952-912-3444 (International).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240221739136/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye